Vuxen Group (VUXEN) Q1 25/26 earnings summary

Executive summary

• Achieved net sales of 52.2 MSEK for Q1 2025/26, a 6.1% increase year-over-year, with EBITDA rising to 4.6 MSEK from 3.9 MSEK.

• Strategic focus on core sexual health segment, now over 90% of total sales, driving higher margins and growth.

• Ongoing restructuring to concentrate resources on most value-creating activities, with potential divestment of non-core segments.

• Expansion in Germany and broader Europe showing early positive results, supporting international growth ambitions.

Financial highlights

• Net sales: 52.2 MSEK (49.2 MSEK), up 6.1% year-over-year.

• Gross margin: 58.0% (58.5%).

• EBITDA: 4.6 MSEK (3.9 MSEK), EBITDA margin: 8.8% (7.9%).

• EBIT: 2.8 MSEK (2.1 MSEK), EBIT margin: 5.4% (4.2%).

• Net result: 2.9 MSEK (1.8 MSEK).

• Solid equity ratio at 75.9% (65.5%).

Outlook and guidance

• Continued focus on profitable growth in sexual health, with further international expansion planned.

• Strategic review may lead to divestment of non-core businesses to accelerate growth in core segment.

• Entering Q2 with strong momentum and expectation of further strategic progress.